A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Patients of cirrhosis aged 18 to 75 years who have no esophageal or gastric varices.
Locations
Other Locations
India
Institute of Liver & Biliary Sciences (ILBS)
RECRUITING
New Delhi
Contact Information
Primary
Dr Ankur Jindal, DM
ankur.jindal3@gmail.com
011-46300000
Backup
Dr Ankit Bhardwaj, PhD (Epidemiology)
bhardwaj.ankit3@gmail.com
01146300000
Time Frame
Start Date: 2010-09-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 132
Treatments
Experimental: Carvedilol
Tablet 6.25 mg BD
Placebo_comparator: placebo
Placebo tablets 2 BD
Related Therapeutic Areas
Sponsors
Leads: Institute of Liver and Biliary Sciences, India